Oppenheimer Initiates Coverage On Legend Biotech with Outperform Rating, Announces Price Target of $75

Benzinga · 5d ago
Oppenheimer analyst Trevor Allred initiates coverage on Legend Biotech (NASDAQ:LEGN) with a Outperform rating and announces Price Target of $75.